IPOPI are seeking the input of patients living with primary immunodeficiency and parents who are taking care of a child with a primary immunodeficiency (under the age of 18 years), using IG replacement therapy who have switched to another brand or mode of administration (intravenous, subcutaneous, facilitated subcutaneous) during the last 2 years.
The survey is available for replies on Survey Monkey